Transcriptome Data and Comparative Medical Analysis of COVID-19 Virus Infection

doi:10.12300/j.issn.1674-5817.2023.079

Abstract

Abstract:

Objective To provide more basic information of comparative medicine for the study of biological changes and pathogenesis of COVID-19 by systematical sorting and analyzing the transcriptome data. Methods Following a retrieval strategy, using COVID-19 and SARS-CoV-2 as key words, transcriptome datasets related to COVID-19 from January 2020 to May 2023 were collected from GEO, ArrayExpress and GEN Transcriptome databases. The composition, distribution, and research application of COVID-19 transcriptome data resources were analyzed. Data distribution was visually displayed and correlation analysis was performed. The research applications and limitations of existing COVID-19 transcriptome data were analyzed from the perspectives of clinical medicine and comparative medicine, focusing on clinical-related molecular mechanisms, biomarkers and related immune responses, treatment intervention strategies, etc. The research value and application prospects were discussed. Results A total of 975 sets of COVID-19 transcriptome data were included. Among three databases, datasets from humans accounted for the highest proportion, namely 71.9%, 77.9%, and 90%, respectively. Species other than humans, such as mice, were the main sources of data, with the respiratory and nervous systems having the highest distribution of data. Twenty-seven datasets were associated with clinical significance. Analysis revealed that respiratory tract injury and other related molecular mechanisms were obtained through transcriptome data mining. Biomarkers such as cfDNA could be used as therapeutic targets. The severity of COVID-19 infection was associated with cell changes and disorders represented by M1 macrophages. Comparative medical analysis showed that mice, hamsters, and other animals were susceptible to SARS-CoV-2. Rhesus monkeys and cynomolgus monkeys exhibited infection characteristics highly similar to human. Apart from respiratory symptoms, hamsters also exhibited digestive system symptoms. SARS-CoV-2 can replicate in the respiratory organs of various susceptible animals, the intestines of ferrets and the ears of minks, resulting in interstitial pneumonia, diffuse lung injury and other pathological changes of varying degrees. Based on the differences in immune responses, hamsters can be used for neutralizing antibody reaction research. Conclusion Currently there is a wealth of COVID-19 transcriptome data, but there is a lack of comparative transcriptome research. Transcriptomics can be combined with comparative medicine to further explore the differences in comparative medicine of COVID-19.

Key words: COVID-19, Transcriptome, Big data, Molecular mechanisms, Data analysis

CLC Number:

R-332

Tingting FENG, Yitong LI, Yue WU, Jue WANG, Qi KONG. Transcriptome Data and Comparative Medical Analysis of COVID-19 Virus Infection[J]. Laboratory Animal and Comparative Medicine, 2024, 44(1): 62-73.

Figures/Tables 8

References 43

1	LOWE R, SHIRLEY N, BLEACKLEY M, et al. Transcriptomics technologies[J]. PLoS Comput Biol, 2017, 13(5): e1005457. DOI: 10.1371/journal.pcbi.1005457 .
2	国家卫生健康委. «关于对新型冠状病毒感染实施"乙类乙管"的总体方案»解读问答[A/OL]. [2023-10-01]. .
	National Health Commission of the People's Republic of China. Questions and answers on "overall plan of implementing 'class B management' for novel coronavirus infection"[J]. [A/OL]. [2023-10-01]. .
3	JHA P K, VIJAY A, HALU A, et al. Gene expression profiling reveals the shared and distinct transcriptional signatures in human lung epithelial cells infected with SARS-CoV-2, MERS-CoV, or SARS-CoV: potential implications in cardiovascular complications of COVID-19[J]. Front Cardiovasc Med, 2021, 7:623012. DOI: 10.3389/fcvm.2020.623012 .
4	CROSS A R, DE ANDREA C E, VILLALBA-ESPARZA M, et al. Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury[J]. JCI Insight, 2023, 8(2): e157837. DOI: 10.1172/jci.insight.157837 .
5	HAMMOUDEH S M, HAMMOUDEH A M, BHAMIDIMARRI P M, et al. Insight into molecular mechanisms underlying hepatic dysfunction in severe COVID-19 patients using systems biology[J]. World J Gastroenterol, 2021, 27(21):2850-2870. DOI: 10.3748/wjg.v27.i21.2850 .
6	MITAMURA Y, SCHULZ D, ORO S, et al. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients[J]. Allergy, 2022, 77(2):595-608. DOI: 10.1111/all.14983 .
7	HIRSCH J S, NG J H, ROSS D W, et al. Acute kidney injury in patients hospitalized with COVID-19[J]. Kidney Int, 2020, 98(1):209-218. DOI: 10.1016/j.kint.2020.05.006 .
8	ALEXANDER M P, MANGALAPARTHI K K, MADUGUNDU A K, et al. Acute kidney injury in severe COVID-19 has similarities to sepsis-associated kidney injury: a multi-omics study[J]. Mayo Clin Proc, 2021, 96(10):2561-2575. DOI: 10.1016/j.mayocp.2021.07.001 .
9	LONG B, BRADY W J, KOYFMAN A, et al. Cardiovascular complications in COVID-19[J]. Am J Emerg Med, 2020, 38(7):1504-1507. DOI: 10.1016/j.ajem.2020.04.048 .
10	WISCOVITCH-RUSSO R, IBÁÑEZ-PRADA E D, SERRANO-MAYORGA C C, et al. Major adverse cardiovascular events are associated with necroptosis during severe COVID-19[J]. Crit Care, 2023, 27(1):155. DOI: 10.1186/s13054-023-04423-8 .
11	CHEN X P, WU T, LI L G, et al. Transcriptional start site coverage analysis in plasma cell-free DNA reveals disease severity and tissue specificity of COVID-19 patients[J]. Front Genet, 2021, 12:663098. DOI: 10.3389/fgene.2021.663098 .
12	GÓMEZ-CARBALLA A, RIVERO-CALLE I, PARDO-SECO J, et al. A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity[J]. Environ Res, 2022, 210:112890. DOI: 10.1016/j.envres.2022.112890 .
13	KRISHNAMOORTHY P, RAJ A S, KUMAR H. Machine learning-driven blood transcriptome-based discovery of SARS-CoV-2 specific severity biomarkers[J]. J Med Virol, 2023, 95(2): e28488. DOI: 10.1002/jmv.28488 .
14	CLANCY J, HOFFMANN C S, PICKETT B E. Transcriptomics secondary analysis of severe human infection with SARS-CoV-2 identifies gene expression changes and predicts three transcriptional biomarkers in leukocytes[J]. Comput Struct Biotechnol J, 2023, 21:1403-1413. DOI: 10.1016/j.csbj.2023.02.003 .
15	LIU Y, WU Y K, LIU B, et al. Biomarkers and immune repertoire metrics identified by peripheral blood transcriptomic sequencing reveal the pathogenesis of COVID-19[J]. Front Immunol, 2021, 12:677025. DOI: 10.3389/fimmu.2021.677025 .
16	ASCHENBRENNER A C, MOUKTAROUDI M, KRÄMER B, et al. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients[J]. Genome Med, 2021, 13(1):7. DOI: 10.1186/s13073-020-00823-5 .
17	ZHANG J Q, LIN D Z, LI K, et al. Transcriptome analysis of peripheral blood mononuclear cells reveals distinct immune response in asymptomatic and re-detectable positive COVID-19 patients[J]. Front Immunol, 2021, 12:716075. DOI: 10.3389/fimmu.2021.716075 .
18	MUKHERJEE S, BANERJEE B, KARASIK D, et al. mRNA-lncRNA co-expression network analysis reveals the role of lncRNAs in immune dysfunction during severe SARS-CoV-2 infection[J]. Viruses, 2021, 13(3):402. DOI: 10.3390/v13030402 .
19	KARAMI H, DERAKHSHANI A, GHASEMIGOL M, et al. Weighted gene co-expression network analysis combined with machine learning validation to identify key modules and hub genes associated with SARS-CoV-2 infection[J]. J Clin Med, 2021, 10(16):3567. DOI: 10.3390/jcm10163567 .
20	HU R W, LIU C, YAN Y Y, et al. Identification of hub genes and molecular subtypes in COVID-19 based on WGCNA[J]. Eur Rev Med Pharmacol Sci, 2021, 25(20):6411-6424. DOI: 10.26355/eurrev_202110_27015 .
21	PANIRI A, AKHAVAN-NIAKI H. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation[J]. Life Sci, 2020, 257:118114. DOI: 10.1016/j.lfs.2020.118114 .
22	VISHNUBALAJI R, SHAATH H, ALAJEZ N M. Protein coding and long noncoding RNA (lncRNA) transcriptional landscape in SARS-CoV-2 infected bronchial epithelial cells highlight a role for interferon and inflammatory response[J]. Genes, 2020, 11(7):760. DOI: 10.3390/genes11070760 .
23	TANG H, GAO Y H, LI Z H, et al. The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID-19[J]. Clin Transl Med, 2020, 10(6): e200. DOI: 10.1002/ctm2.200 .
24	LIAO M F, LIU Y, YUAN J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19[J]. Nat Med, 2020, 26(6):842-844. DOI: 10.1038/s41591-020-0901-9 .
25	ZHANG Z L, CUI F F, CAO C, et al. Single-cell RNA analysis reveals the potential risk of organ-specific cell types vulnerable to SARS-CoV-2 infections[J]. Comput Biol Med, 2021, 140:105092. DOI: 10.1016/j.compbiomed.2021.105092 .
26	FILBIN M R, MEHTA A, SCHNEIDER A M, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions[J]. Cell Rep Med, 2021, 2(5):100287. DOI: 10.1016/j.xcrm.2021.100287 .
27	FUZO C A, FRAGA-SILVA T F C, MARUYAMA S R, et al. The turning point of COVID-19 severity is associated with a unique circulating neutrophil gene signature[J]. Immunology, 2023, 169(3):323-343. DOI: 10.1111/imm.13631 .
28	SCHIMKE L F, MARQUES A H C, BAIOCCHI G C, et al. Severe COVID-19 shares a common neutrophil activation signature with other acute inflammatory states[J]. Cells, 2022, 11(5):847. DOI: 10.3390/cells11050847 .
29	UTRERO-RICO A, GONZÁLEZ-CUADRADO C, CHIVITE-LACABA M, et al. Alterations in circulating monocytes predict COVID-19 severity and include chromatin modifications still detectable six months after recovery[J]. Biomedicines, 2021, 9(9):1253. DOI: 10.3390/biomedicines 9091253 .
30	YANG A C, KERN F, LOSADA P M, et al. Publisher Correction: Dysregulation of brain and choroid plexus cell types in severe COVID-19[J]. Nature, 2021, 598(7882): E4. DOI: 10.1038/s41586-021-04080-3 .
31	吴玥, 薛婧, 魏强, 等. 国家动物模型资源共享信息平台的建立[J]. 中国实验动物学报, 2022, 30(8): 1080-1086. DOI: 10.3969/j.issn.1005-4847.2022.08.009 .
	WU Y, XUE J, WEI Q, et al. Establishment of national infrastructure for an animal model resource platform[J]. Acta Lab Animalis Sci Sin, 2022, 30(8): 1080-1086. DOI: 10.3969/j.issn.1005-4847.2022.08.009 .
32	ZHENG J X, DENG Y Y, ZHAO Z Y, et al. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects[J]. Cell Mol Immunol, 2022, 19(2):150-157. DOI: 10.1038/s41423-021-00774-w .
33	BAO L L, DENG W, HUANG B Y, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice[J]. Nature, 2020, 583(7818):830-833. DOI: 10.1038/s41586-020-2312-y .
34	CHAN J F W, ZHANG A J, YUAN S F, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian Hamster model: implications for disease pathogenesis and transmissibility[J]. Clin Infect Dis, 2020, 71(9):2428-2446. DOI: 10.1093/cid/ciaa325 .
35	KIM Y I, KIM S G, KIM S M, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets[J]. Cell Host Microbe, 2020, 27(5):704-709.e2. DOI: 10.1016/j.chom.2020.03.023 .
36	SHUAI L, ZHONG G X, YUAN Q, et al. Replication, pathogenicity, and transmission of SARS-CoV-2 in minks[J]. Natl Sci Rev, 2021, 8(3): nwaa291. DOI: 10.1093/nsr/nwaa291 .
37	SHAN C, YAO Y F, YANG X L, et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques[J]. Cell Res, 2020, 30(8):670-677. DOI: 10.1038/s41422-020-0364-z .
38	吴玥, 向志光, 高苒, 等. 冠状病毒感染动物模型比较转录组学数据库的建立[J]. 中国实验动物学报, 2022, 30(1):92-99. DOI: 10.3969/j.issn.1005-4847.2022.01.012 .
	WU Y, XIANG Z G, GAO R, et al. Establishment of a comparative transcriptomics database of coronavirus infected animal models[J]. Acta Lab Anim Sci Sinica, 2022, 30(1):92-99. DOI: 10.3969/j.issn.1005-4847.2022.01.012 .
39	REN X W, WEN W, FAN X Y, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas[J]. Cell, 2021, 184(7):1895-1913.e19. DOI: 10.1016/j.cell.2021.01.053 .
40	MECKIFF B J, RAMÍREZ-SUÁSTEGUI C, FAJARDO V, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19[J]. Cell, 2020, 183(5):1340-1353.e16. DOI: 10.1016/j.cell.2020.10.001 .
41	NAGAFUCHI Y, YANAOKA H, FUJIO K. Lessons from transcriptome analysis of autoimmune diseases[J]. Front Immunol, 2022, 13:857269. DOI: 10.3389/fimmu.2022.857269 .
42	ROBINSON E L, BAKER A H, BRITTAN M, et al. Dissecting the transcriptome in cardiovascular disease[J]. Cardiovasc Res, 2022, 118(4):1004-1019. DOI: 10.1093/cvr/cvab117 .
43	PARK H W, WEISS S T. Understanding the molecular mechanisms of asthma through transcriptomics[J]. Allergy Asthma Immunol Res, 2020, 12(3):399-411. DOI: 10.4168/aair.2020.12.3.399 .

样本来源 Sample origins	组织/细胞 Tissues/cells	发现 Finding	数据集编号 Datasets' number
人；雪貂 Human; ferrets	NHBE、A549、Calu3细胞，肺组织（人）；鼻腔冲洗液（雪貂）	新冠病毒感染肺损伤相关机制	GSE147507
人；雪貂 Human; ferrets	NHBE、A549、Calu3细胞（人）；鼻腔冲洗液（雪貂）	应对新冠病毒感染时NHBE细胞上调MALAT1和NEAT1表达	GSE147507
人；C57BL/6小鼠 Human; C57BL/6 mice	PBMC、肺泡灌洗液（人）；淋巴结（小鼠）	髓细胞、上皮细胞和T细胞之间的相互作用驱动组织损伤	GSE149689； GSE155673; GSE145926; GSE149443
金黄仓鼠 Golden hamsters	心脏	新冠病毒感染对心脏的损伤机制	PRJNA884511
人Human	肺、肝脏	新冠病毒感染肝损伤相关机制	GSE150316
人Human	肺泡灌洗液	严重新冠病毒感染患者的支气管肺泡灌洗液中富含促炎单核细胞衍生的巨噬细胞	GSE145926
人Human	肺泡灌洗液	M1型巨噬细胞和重度新冠病毒感染患者之间的关系最高	GSE145926
人Human	肺泡灌洗液	在重症监护室的新冠病毒感染患者中，中性粒细胞高度激活	EGAS00001004571 (EGA)
人Human	皮肤	新冠病毒感染引起皮疹机制	GSE161225
人Human	血液、鼻上皮、唾液	CCL3等基因为严重新冠病毒感染鼻腔、口腔和血液中的生物标志物	GSE183071
人Human	上呼吸道、鼻咽、全血	发现与新冠病毒感染每种分子亚型相关的特定基因	GSE156063; GSE163151
人Human	外周血、全血、血浆和白细胞	ARG1等7个基因生物标志物可区分SARS-CoV-2相关的ARI和其他类型的ARI	GSE161731; GSE171110 GSE152641; GSE157103 GSE172114; GSE161777
人Human	PBMC、全血、血浆和白细胞	生物标志物TGFBI、TTYH2和CD4参与免疫反应和炎症	GSE152418; GSE166424; GSE157103
人Human	全血	新冠病毒感染严重程度的转折点与S100A9等8个中性粒细胞特征基因有关	E-MTAB-11240 (EMBL-EBI)
人Human	外周血	神经损伤相关的UCHL1表达增加与严重症状有关	GSE152418
人Human	外周血	miR-146-146a-5p等3个非编码RNA是新冠病毒感染的潜在治疗靶点	HRA000238 (NGDC)
人Human	外周血	鉴定了6个具有不同分子特征的新冠肺炎亚型	GSE143507
人Human	血沉棕黄层细胞、A549细胞	cfDNA能够作为查看疾病严重程度的非侵入性生物标志物	GSE147507; GSE154998
人Human	PBMC	无症状患者中PBMC的免疫反应较弱，复阳患者的PBMC具有高炎症免疫反应	GSE179627
人Human	PBMC	循环单核淋巴细胞的变化可预测新冠病毒感染的严重程度	GSE180594
人Human	额叶皮质、脉络丛	新冠病毒感染患者脑和脉络丛细胞的功能失调	GSE159812

样本来源 Sample origins	组织/细胞 Tissues/cells	发现 Finding	数据集编号 Datasets' number
人；雪貂 Human; ferrets	NHBE、A549、Calu3细胞，肺组织（人）；鼻腔冲洗液（雪貂）	新冠病毒感染肺损伤相关机制	GSE147507
人；雪貂 Human; ferrets	NHBE、A549、Calu3细胞（人）；鼻腔冲洗液（雪貂）	应对新冠病毒感染时NHBE细胞上调MALAT1和NEAT1表达	GSE147507
人；C57BL/6小鼠 Human; C57BL/6 mice	PBMC、肺泡灌洗液（人）；淋巴结（小鼠）	髓细胞、上皮细胞和T细胞之间的相互作用驱动组织损伤	GSE149689； GSE155673; GSE145926; GSE149443
金黄仓鼠 Golden hamsters	心脏	新冠病毒感染对心脏的损伤机制	PRJNA884511
人Human	肺、肝脏	新冠病毒感染肝损伤相关机制	GSE150316
人Human	肺泡灌洗液	严重新冠病毒感染患者的支气管肺泡灌洗液中富含促炎单核细胞衍生的巨噬细胞	GSE145926
人Human	肺泡灌洗液	M1型巨噬细胞和重度新冠病毒感染患者之间的关系最高	GSE145926
人Human	肺泡灌洗液	在重症监护室的新冠病毒感染患者中，中性粒细胞高度激活	EGAS00001004571 (EGA)
人Human	皮肤	新冠病毒感染引起皮疹机制	GSE161225
人Human	血液、鼻上皮、唾液	CCL3等基因为严重新冠病毒感染鼻腔、口腔和血液中的生物标志物	GSE183071
人Human	上呼吸道、鼻咽、全血	发现与新冠病毒感染每种分子亚型相关的特定基因	GSE156063; GSE163151
人Human	外周血、全血、血浆和白细胞	ARG1等7个基因生物标志物可区分SARS-CoV-2相关的ARI和其他类型的ARI	GSE161731; GSE171110 GSE152641; GSE157103 GSE172114; GSE161777
人Human	PBMC、全血、血浆和白细胞	生物标志物TGFBI、TTYH2和CD4参与免疫反应和炎症	GSE152418; GSE166424; GSE157103
人Human	全血	新冠病毒感染严重程度的转折点与S100A9等8个中性粒细胞特征基因有关	E-MTAB-11240 (EMBL-EBI)
人Human	外周血	神经损伤相关的UCHL1表达增加与严重症状有关	GSE152418
人Human	外周血	miR-146-146a-5p等3个非编码RNA是新冠病毒感染的潜在治疗靶点	HRA000238 (NGDC)
人Human	外周血	鉴定了6个具有不同分子特征的新冠肺炎亚型	GSE143507
人Human	血沉棕黄层细胞、A549细胞	cfDNA能够作为查看疾病严重程度的非侵入性生物标志物	GSE147507; GSE154998
人Human	PBMC	无症状患者中PBMC的免疫反应较弱，复阳患者的PBMC具有高炎症免疫反应	GSE179627
人Human	PBMC	循环单核淋巴细胞的变化可预测新冠病毒感染的严重程度	GSE180594
人Human	额叶皮质、脉络丛	新冠病毒感染患者脑和脉络丛细胞的功能失调	GSE159812

物种 Species	常用品种/品系 Breeds/ strains in common use	感染滴度或剂量 Infection titer or dose	感染途径 Routes of infection	用途 Applications	优点 Advantages	缺点 Disadvantages	GEO数据集数量 Number of GEO datasets
小鼠 Mice	hACE2转基因小鼠	1×10⁵ TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	方便，便宜	耗时	21
小鼠 Mice	K18-hACE2小鼠	1×10² TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	方便，便宜	非致死模型	9
小鼠 Mice	hACE2-KI人源化小鼠	4×10⁵ PFU	滴鼻	病毒感染抗体评价，疫苗评价	方便，便宜	非致死模型	-
仓鼠 Hamsters	金黄地鼠	8×10⁴ TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	便宜，有消化系统症状	操作不如小鼠方便，病毒7 d清除，不致死	41
雪貂 Ferrets	-	1×10⁵ PFU	滴鼻	致病机制研究，疫苗和药物评估	能通过直接接触和气溶胶感染	检测不如小鼠经济	5
猴 Monkeys	恒河猴	1×10⁶ TCID₅₀	经气管感染	致病机制研究，疫苗和药物评估	与人类高度相似	价格昂贵	25
猴 Monkeys	食蟹猴	1×10⁶ PFU	气管、鼻腔、黏膜联合感染	评价新冠药物与疫苗	与人类高度相似	价格昂贵	8
水貂 Minks	-	1×10⁶ TCID₅₀	经气管感染	临床病理机制阐述，药物和疫苗评价，生物标志物筛选	与人类症状较为相似	应用少，相关试剂较少	-
树鼩 Tree shrews	-	1×10⁷ TCID₅₀	口、气管、眼联合感染	药物筛选和疫苗评估	便宜，与灵长类相似	没有纯遗传背景的品系，个体差异较大	-

物种 Species	常用品种/品系 Breeds/ strains in common use	感染滴度或剂量 Infection titer or dose	感染途径 Routes of infection	用途 Applications	优点 Advantages	缺点 Disadvantages	GEO数据集数量 Number of GEO datasets
小鼠 Mice	hACE2转基因小鼠	1×10⁵ TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	方便，便宜	耗时	21
小鼠 Mice	K18-hACE2小鼠	1×10² TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	方便，便宜	非致死模型	9
小鼠 Mice	hACE2-KI人源化小鼠	4×10⁵ PFU	滴鼻	病毒感染抗体评价，疫苗评价	方便，便宜	非致死模型	-
仓鼠 Hamsters	金黄地鼠	8×10⁴ TCID₅₀	滴鼻	致病机制研究，疫苗和药物评估	便宜，有消化系统症状	操作不如小鼠方便，病毒7 d清除，不致死	41
雪貂 Ferrets	-	1×10⁵ PFU	滴鼻	致病机制研究，疫苗和药物评估	能通过直接接触和气溶胶感染	检测不如小鼠经济	5
猴 Monkeys	恒河猴	1×10⁶ TCID₅₀	经气管感染	致病机制研究，疫苗和药物评估	与人类高度相似	价格昂贵	25
猴 Monkeys	食蟹猴	1×10⁶ PFU	气管、鼻腔、黏膜联合感染	评价新冠药物与疫苗	与人类高度相似	价格昂贵	8
水貂 Minks	-	1×10⁶ TCID₅₀	经气管感染	临床病理机制阐述，药物和疫苗评价，生物标志物筛选	与人类症状较为相似	应用少，相关试剂较少	-
树鼩 Tree shrews	-	1×10⁷ TCID₅₀	口、气管、眼联合感染	药物筛选和疫苗评估	便宜，与灵长类相似	没有纯遗传背景的品系，个体差异较大	-

物种 Species	病毒复制部位 Virus replication site	病理变化 Pathological change	免疫应答 Immune response	参考文献 References
人类 Human	主要在呼吸道和肠道	肺炎，急性呼吸窘迫综合征	产生针对S和N蛋白以及RBD的IgG抗体	[32]
小鼠（hACE2转基因小鼠） Mice( hACE2 transgenic mice )	肺	间质性肺炎	产生抗S蛋白的特异性抗体	[33]
仓鼠 Hamsters	肺、鼻甲、气管、肠道	肺炎，弥漫性肺泡损伤	中和抗体反应，IFN-R、IL-4、IL-6、TNF-a、 IL-12p40上调中和抗体反应	[34]
雪貂 Ferrets	鼻甲、气管、肺、肠道	毛细支气管炎	-	[35]
水貂 Minks	鼻腔、直肠、耳	间质性肺炎，血管周炎，细支气管周炎，鼻黏膜损伤	-	[36]
恒河猴 Rhesus monkey	肺、气管、支气管	间质性肺炎	白细胞和中性粒细胞减少，淋巴细胞增加	[37]